GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Shiller PE Ratio

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Shiller PE Ratio : (As of May. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aerie Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Aerie Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Shiller PE Ratio Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aerie Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Shiller PE Ratio falls into.



Aerie Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aerie Pharmaceuticals's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, Aerie Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.56/125.2265*125.2265
=-0.560

Current CPI (Sep. 2022) = 125.2265.

Aerie Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 -0.240 96.871 -0.310
201303 -0.248 98.209 -0.316
201306 -0.408 98.518 -0.519
201309 -0.490 98.790 -0.621
201312 -0.620 98.326 -0.790
201403 -0.280 99.695 -0.352
201406 -0.490 100.560 -0.610
201409 -0.540 100.428 -0.673
201412 -0.690 99.070 -0.872
201503 -0.700 99.621 -0.880
201506 -0.730 100.684 -0.908
201509 -0.690 100.392 -0.861
201512 -0.760 99.792 -0.954
201603 -0.850 100.470 -1.059
201606 -0.870 101.688 -1.071
201609 -0.810 101.861 -0.996
201612 -0.870 101.863 -1.070
201703 -0.760 102.862 -0.925
201706 -0.820 103.349 -0.994
201709 -0.890 104.136 -1.070
201712 -1.600 104.011 -1.926
201803 -1.050 105.290 -1.249
201806 -1.400 106.317 -1.649
201809 -1.960 106.507 -2.304
201812 -1.140 105.998 -1.347
201903 -1.060 107.251 -1.238
201906 -1.040 108.070 -1.205
201909 -1.090 108.329 -1.260
201912 -1.210 108.420 -1.398
202003 -1.070 108.902 -1.230
202006 -1.050 108.767 -1.209
202009 -0.860 109.815 -0.981
202012 -1.000 109.897 -1.139
202103 -0.910 111.754 -1.020
202106 -0.840 114.631 -0.918
202109 -0.860 115.734 -0.931
202112 0.960 117.630 1.022
202203 -0.760 121.301 -0.785
202206 -0.410 125.017 -0.411
202209 -0.560 125.227 -0.560

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aerie Pharmaceuticals  (NAS:AERI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aerie Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines

From GuruFocus

Top 5 4th Quarter Trades of PINNACLE ASSOCIATES LTD

By GuruFocus Research GuruFocus Editor 01-25-2023